Agence de Médecine Préventive, France Report issue

Government Phase 4

Organization Overview

First Clinical Trial
2013
NCT01577771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Agence de Médecine Préventive, France

Active Ingredients

Drugs in Phase 4 Trials (1)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumococcal Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1